173 related articles for article (PubMed ID: 15577263)
1. [Pharmaceutical application of cyclodextrins as multi-functional drug carriers].
Uekama K
Yakugaku Zasshi; 2004 Dec; 124(12):909-35. PubMed ID: 15577263
[TBL] [Abstract][Full Text] [Related]
2. Design and evaluation of cyclodextrin-based drug formulation.
Uekama K
Chem Pharm Bull (Tokyo); 2004 Aug; 52(8):900-15. PubMed ID: 15304981
[TBL] [Abstract][Full Text] [Related]
3. [Novel approach of cyclodextrin-based pharmaceutical formulation].
Uekama K
Yakugaku Zasshi; 2012; 132(1):85-105. PubMed ID: 22214584
[TBL] [Abstract][Full Text] [Related]
4. [Development and pharmaceutical evaluation of hydrophobic cyclodextrin derivatives as modified-release drug carriers].
Hirayama F
Yakugaku Zasshi; 1993 Jun; 113(6):425-37. PubMed ID: 8355145
[TBL] [Abstract][Full Text] [Related]
5. Stabilizing and solubilizing effects of sulfobutyl ether beta-cyclodextrin on prostaglandin E1 analogue.
Uekama K; Hieda Y; Hirayama F; Arima H; Sudoh M; Yagi A; Terashima H
Pharm Res; 2001 Nov; 18(11):1578-85. PubMed ID: 11758766
[TBL] [Abstract][Full Text] [Related]
6. Some pharmaceutical properties of 3-hydroxypropyl- and 2,3-dihydroxypropyl-beta-cyclodextrins and their solubilizing and stabilizing abilities.
Yoshida A; Yamamoto M; Irie T; Hirayama F; Uekama K
Chem Pharm Bull (Tokyo); 1989 Apr; 37(4):1059-63. PubMed ID: 2766408
[TBL] [Abstract][Full Text] [Related]
7. Potential Use of Cyclodextrins as Drug Carriers and Active Pharmaceutical Ingredients.
Arima H; Motoyama K; Higashi T
Chem Pharm Bull (Tokyo); 2017; 65(4):341-348. PubMed ID: 28381674
[TBL] [Abstract][Full Text] [Related]
8. Enhanced rectal absorption and reduced local irritation of the anti-inflammatory drug ethyl 4-biphenylylacetate in rats by complexation with water-soluble beta-cyclodextrin derivatives and formulation as oleaginous suppository.
Arima H; Kondo T; Irie T; Uekama K
J Pharm Sci; 1992 Nov; 81(11):1119-25. PubMed ID: 1447717
[TBL] [Abstract][Full Text] [Related]
9. Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats.
Arima H; Yunomae K; Miyake K; Irie T; Hirayama F; Uekama K
J Pharm Sci; 2001 Jun; 90(6):690-701. PubMed ID: 11357172
[TBL] [Abstract][Full Text] [Related]
10. Cyclodextrin-based controlled drug release system.
Hirayama F; Uekama K
Adv Drug Deliv Rev; 1999 Mar; 36(1):125-141. PubMed ID: 10837712
[TBL] [Abstract][Full Text] [Related]
11. [Use of water-soluble beta-cyclodextrin derivatives as carriers of anti-inflammatory drug biphenylylacetic acid in rectal delivery].
Arima H; Kondo T; Irie T; Hirayama F; Uekama K; Miyaji T; Inoue Y
Yakugaku Zasshi; 1992 Jan; 112(1):65-72. PubMed ID: 1578346
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in cyclodextrin delivery techniques.
Arima H; Hayashi Y; Higashi T; Motoyama K
Expert Opin Drug Deliv; 2015; 12(9):1425-41. PubMed ID: 26098975
[TBL] [Abstract][Full Text] [Related]
13. Effects of cyclodextrins on chemically and thermally induced unfolding and aggregation of lysozyme and basic fibroblast growth factor.
Tavornvipas S; Hirayama F; Takeda S; Arima H; Uekama K
J Pharm Sci; 2006 Dec; 95(12):2722-9. PubMed ID: 16917853
[TBL] [Abstract][Full Text] [Related]
14. Release characteristics of endogenous constituents by exposure of small intestine to modified beta-cyclodextrins.
Tanino T; Ogiso T; Iwaki M; Yamaguchi T; Kakehi K
Biol Pharm Bull; 1999 Oct; 22(10):1099-105. PubMed ID: 10549863
[TBL] [Abstract][Full Text] [Related]
15. Peracylated beta-cyclodextrins as novel sustained-release carriers for a water-soluble drug, molsidomine.
Uekama K; Horikawa T; Yamanaka M; Hirayama F
J Pharm Pharmacol; 1994 Sep; 46(9):714-7. PubMed ID: 7837039
[TBL] [Abstract][Full Text] [Related]
16. Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins.
Sharma US; Balasubramanian SV; Straubinger RM
J Pharm Sci; 1995 Oct; 84(10):1223-30. PubMed ID: 8801338
[TBL] [Abstract][Full Text] [Related]
17. Some pharmaceutical and inclusion properties of 2-hydroxybutyl-β-cyclodextrin derivative.
Ishiguro T; Morishita E; Iohara D; Hirayama F; Wada K; Motoyama K; Arima H; Uekama K
Int J Pharm; 2011 Oct; 419(1-2):161-9. PubMed ID: 21839823
[TBL] [Abstract][Full Text] [Related]
18. Effects of hydrophilic cyclodextrins on aggregation of recombinant human growth hormone.
Tavornvipas S; Tajiri S; Hirayama F; Arima H; Uekama K
Pharm Res; 2004 Dec; 21(12):2369-76. PubMed ID: 15648271
[TBL] [Abstract][Full Text] [Related]
19. Involvement of PI3K-Akt-Bad pathway in apoptosis induced by 2,6-di-O-methyl-beta-cyclodextrin, not 2,6-di-O-methyl-alpha-cyclodextrin, through cholesterol depletion from lipid rafts on plasma membranes in cells.
Motoyama K; Kameyama K; Onodera R; Araki N; Hirayama F; Uekama K; Arima H
Eur J Pharm Sci; 2009 Oct; 38(3):249-61. PubMed ID: 19664706
[TBL] [Abstract][Full Text] [Related]
20. Improvement of some physicochemical properties of arundic acid, (R)-(-)-2-propyloctanonic acid, by complexation with hydrophilic cyclodextrins.
Miyamoto Y; Nakahara M; Motoyama K; Ishiguro T; Oda Y; Yamanoi T; Okamoto I; Yagi A; Nishimura H; Hirayama F; Uekama K; Arima H
Int J Pharm; 2011 Jul; 413(1-2):63-72. PubMed ID: 21540089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
